Fevigra

• Hypoactive Sexual Desire Disorder (HSDD): Indicated for premenopausal women with acquired, generalized HSDD characterized by low sexual desire that causes marked distress or interpersonal difficulty.

The mechanism of action of Flibanserin is not known. Flibanserin demonstrated high affinity for 5-HTIA and 5-HT2A receptors, showing agonist activity on 5-HTIA and antagonist on 5-HT2A, resulting in lowering of serotonin in the brain as well as effect on increasing norepinephrine and dopamine neurotransmitters.

Adult Dose (Oral):

• 100 mg PO once daily at bedtime.
• Discontinue after 8 weeks if no improvement.

Child Dose: Not recommended in patients below 18 years.

Common Side Effects (>10%):

• Dizziness (11.4%)
• Somnolence (11.2%)
• Nausea (10.4%)

Uncommon Side Effects (1-10%):

• Fatigue (9.2%)
• Insomnia (4.9%)
• Dry mouth (2.4%)
• Anxiety (1.8%)
• Constipation (1.6%)
• Abdominal pain (1.5%)
• Metrorrhagia (1.4%)
• Rash (1.3%)
• Sedation (1.3%)
• Vertigo (1%)

Use in Pregnancy: No studies in pregnant women; animal studies showed fetal toxicity only in presence of significant maternal toxicity.

Precautions:

• Coadministration with alcohol increases risk of severe hypotension and syncope (contraindicated).
• Coadministration with moderate or strong CYP3A4 inhibitors significantly increases flibanserin concentrations (contraindicated).
• Causes CNS depression (somnolence, sedation); risk increased if taken during waking hours, or with alcohol or other CNS depressants.
• Hypotension and syncope can also occur with flibanserin taken alone.
• Avoid activities requiring full alertness (operating machinery or driving) until at least 6 hours after each dose.

Overdose: Limited information on overdose; symptomatic treatment.

Storage: Keep below 30 degree C, away from light and moisture. Keep out of reach of children.